Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Fidia SpA designs, produces and distributes integrated milling systems, which is applied in the manufacturing of molds and dies for automotive industry and in aerospace field. It also provide solutions for the complete milling process, from the definition of the machining program to the finished product. The company was founded by Giuseppe Morfino in 1974 and is headquartered in San Mauro Torinese, Italy.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Specializes in biopharmaceutical products with focus in immunotherapy for the treatment of cancer

Mediterranea Theranostic Srl is a private company headquartered in Italy that develops anticancer drugs and diagnostic tests.

Researches biotechnology on new virus technology

Skillcell SAS is a French private company located in Baie Mahault that provides biotechnology research and development services. It was founded in 2017.

Center for Applied Molecular Research Salamanca (doing business as CIBASA) is a Spanish private company located in Salamanca that engages in research and development of biotechnology.

Polifarma Spa is an Italian company with the values ​​that characterize the company philosophy, in the foreground, there is the attention to the person. It is a client or collaborator, result orientation, dynamism, and innovation. It is specialized in expertise and intensive research for innovative, effective, and high-quality solutions.

Pharmaleads aims to provide patients suffering from severe chronic and acute pain with improved pain relief without the side effects associated with other classes of analgesics. Based on years of experience in the design of highly potent and specific inhibitors of enkephalinases, Pharmaleads has developed a new class of analgesics called DENKIs (Dual Enkephalinases inhibitors). These small molecules are able to provide patients with local and sustainable pain relief. Pharmaleads’ DENKIs are first-in-class drugs with a novel mechanism of action tackling pain by using endogenous enkephalins, natural peptides that specifically bind to pain-related opioid receptors to naturally modulate pain without the side effects observed with exogenous opioid drugs that also bind to other opioids receptors, not involved in pain control, triggering multiple side effects. Pharmaleads believes its products can change the lives of the many patients who are in need of improved treatment options for their chronic and/or acute pain, and could offer healthcare providers with an improved pain management option that helps address the opioid epidemic.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain.

Laboratorios Salvat develops and manufactures pharmaceutical products. It offers antiseptics, analgesics, antipyretics, and antibiotics. The company was founded in 1955 and is headquartered in Esplugues de Llobregat, Spain.

ALCEDIAG products and services are based on the study of RNA editing, an epigenetic mechanism, and include: A set of blood-based diagnostic solutions; A biomarker discovery platform; A catalog of cell tests. ALCEDIAG develops and commercializes blood-based diagnostic solutions for mental health. ALCEDIAG tests, which combine biology and epigenetics, have two major advantages: To be fully objective as the tests measure biological biomarkers and include no empirical aspect or bias. To be dynamic, since epigenetic markers, including ALCEDIAG biomarkers, evolve in time along with the evolution of the pathologies, the impact of treatment, etc. ALCEDIAG solutions support the entire patient management chain from initial diagnostics to monitoring and remission. Thanks to its game changing technology, its cohorts of more than 600 patients and its experience, ALCEDIAG aims to: Answer the unmet medical need of mental health diagnosis, which combines challenging patient assessment, serious side effects (including suicide), limited responder rates, etc. Create value and business opportunities for both ALCEDIAG and its partners by commercializing highly differentiating solutions. ALCEDIAG has developed a biomarker discovery platform that is used to serve the company’s R&D needs, as well as the ones of third parties. ALCEDIAG methodology combines biological and network analyses to identify innovative biomarkers and biological signatures specific to mental health disorders, which will help to diagnose and manage patients. Beyond mental health diseases, this platform can be used for a large range of pathologies including neurodegenerative disorders, inflammatory diseases and cancers. ALCEDIAG has developed a catalog of cell tests to mimic drugs impact on RNA editing in patients. In addition, the company commercializes a proprietary cell test to anticipate drugs adverse psychiatric side effects.

Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.

INSERM Transfert SA is a Venture Capital firm, a subsidiary of Institut National de la Sant? et de la Recherche M?dicale founded in 2000. INSERM Transfert SA is headquartered in Paris, France.

Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd, a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business. Headquartered in Woodcliff Lake, New Jersey, they are dedicated to a tradition of genuine concern for people and are driven by the desire to help meet the diverse health care needs of patients and their families and caregivers. They are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd., which has a strong and lasting commitment to the U.S. market. Their heritage and mission have earned us recognition as an innovative, efficient, solution-oriented pharmaceutical company - a company that effectively works with healthcare professionals, hospitals and managed care organizations to develop and market specialty products that help address unmet needs. Their ability to forge strong alliances gives us a competitive edge. In the United States, their rapid growth and strong performance result from putting patients and their families first when making decisions and from empowering the people who manage their operations. Eisai employees personify their values of integrity, respect, professionalism, quality and teamwork.